Myriad Genetics, Inc. Provides Unaudited Earnings Guidance for the Fourth Quarter and Full-Year Ended December 31, 2024 and Full-Year of 2025
Published on 01/15/2025 at 08:30
Share
Myriad Genetics, Inc. provided unaudited earnings guidance for the fourth quarter and full-year ended December 31, 2024 and full year of 2025. For the fourth quarter, the company expects total revenues to be between $209 million and $211 million, an increase of approximately 6% to 7% compared to fourth quarter of 2023. Fourth quarter of 2024 GAAP diluted loss per share to be between $0.72 and $0.62. Fourth quarter of 2024 GAAP net loss to be between $65.7 million and $56.8 million.
For the full year of 2024, the company expects total revenues to be between $836 million to $838 million, an increase of approximately 11% compared to full year 2023. Full year 2024 GAAP loss per share to be between $1.66 and $1.56. Full year 2024 GAAP loss to be between $151 million and $142 million.
For the full year of 2025, the company expects revenue to be between $840 million to $860 million. Reflects an increase of approximately 0% and 3% compared to preliminary 2024 revenue and an increase of approximately 8% and 11% compared to preliminary 2024 revenue excluding approximately $45 million of 2024 GeneSight revenue associated with UnitedHealthcare (UNH) commercial and select managed Medicaid plans, approximately $10 million of 2024 revenue from UNH due to a change in estimated revenue related to prior years, and approximately $6 million of 2024 EndoPredict revenue outside the United States associated with the divestiture of the EndoPredict business on August 1, 2024.
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test which can reveal a baby's gender as early as six weeks into pregnancy. The Companyâs testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor Test, Precise Liquid Test, SneakPeek and GeneSight, among others.
